Hypocomplementemic Atypical IgA Vasculitis: A Case Report
暂无分享,去创建一个
[1] Hong Zhang,et al. Collectin11 and Complement Activation in IgA Nephropathy , 2021, Clinical journal of the American Society of Nephrology : CJASN.
[2] M. Szczepańska,et al. IgA vasculitis with nephritis in children. , 2020, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.
[3] S. Ozen,et al. Different histological classifications for Henoch-Schönlein purpura nephritis: which one should be used? , 2019, Pediatric Rheumatology.
[4] G. Remuzzi,et al. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN , 2018, Front. Immunol..
[5] A. Gharavi,et al. Mycophenolate Mofetil in Combination with Steroids for Treatment of C3 Glomerulopathy: A Case Series. , 2018, Clinical journal of the American Society of Nephrology : CJASN.
[6] Yusuke Suzuki,et al. IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis. , 2018, Kidney international.
[7] F. Berthoux,et al. Deletion Variants of CFHR1 and CFHR3 Associate with Mesangial Immune Deposits but Not with Progression of IgA Nephropathy. , 2017, Journal of the American Society of Nephrology : JASN.
[8] John D Lambris,et al. The renaissance of complement therapeutics , 2018, Nature Reviews Nephrology.
[9] T. Cavero,et al. Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. , 2015, Kidney international.
[10] D. Karpman,et al. Eculizumab treatment for rescue of renal function in IgA nephropathy , 2014, Pediatric Nephrology.
[11] V. D’Agati,et al. C3 glomerulopathy: consensus report , 2013, Kidney international.
[12] T. Yoo,et al. Decreased Circulating C3 Levels and Mesangial C3 Deposition Predict Renal Outcome in Patients with IgA Nephropathy , 2012, PloS one.
[13] Xiaozhong Li,et al. Henoch–Schönlein purpura with hypocomplementemia , 2012, Pediatric Nephrology.
[14] J. Davin. Henoch-Schonlein purpura nephritis: pathophysiology, treatment, and future strategy. , 2011, Clinical journal of the American Society of Nephrology : CJASN.
[15] B. Preston,et al. Case Series , 2010, Toxicologic pathology.
[16] L. Jara,et al. Hypocomplementemic urticarial vasculitis syndrome , 2009, Current rheumatology reports.
[17] D. Cattran,et al. Remission of resistant MPGN type I with mycophenolate mofetil and steroids , 2009, Pediatric Nephrology.
[18] T. Ha,et al. A Case of Hypocomplementemic Henoch-Schonlein Purpura Presenting Features of Membranoproliferative Glomerulonephritis , 2005 .
[19] M. Harber,et al. Treatment of idiopathic membranoproliferative glomerulonephritis with mycophenolate mofetil and steroids. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[20] S. Mrusek,et al. Henoch-Schönlein purpura , 2004, The Lancet.
[21] C. Dilber,et al. Is low serum complement 3 in Henoch Schönlein purpura unusual and of prognostic value? , 2001, European Journal of Pediatrics.
[22] I. T. Ten Berge,et al. What is the difference between IgA nephropathy and Henoch-Schönlein purpura nephritis? , 2001, Kidney international.
[23] H. Tamary,et al. Low serum C3, leukopenia, and thrombocytopenia: unusual features of Henoch-Schonlein purpura , 1999, European Journal of Pediatrics.
[24] J. Feehally,et al. Abnormal IgA glycosylation in Henoch-Schönlein purpura restricted to patients with clinical nephritis. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[25] B. Pipy,et al. Henoch-Schönlein purpura and membranoproliferative-like glomerulonephritis. , 1996, Nephron.
[26] I A Mjör,et al. Consensus Report , 1985, Journal of dental research.
[27] C. Chantler,et al. Serum complement components in Henoch-Schönlein purpura. , 1978, Archives of disease in childhood.